Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | CHRNB2 | P17787 | 12/20 | 0.53 |
| ▸ | CHRNA3 | P32297 | 12/20 | 0.53 |
| ▸ | CHRNA4 | P43681 | 12/20 | 0.53 |
| ▸ | CHRNB3 | Q05901 | 12/20 | 0.53 |
| ▸ | CHRNA6 | Q15825 | 12/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25409415 | 1.00 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL1979623 | 1.00 | NR1H2 (0.56) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL22169156 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL24884312 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL608991 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL400513 | 0.91 | NR1H2 (0.50) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| Hydrochloric Acid SCHEMBL7149386 | 0.89 | NR1H2 (0.49) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL18081207 | 0.87 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5242607 | 0.87 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL5241504 | 0.87 | NR1H2 (0.47) | NR1H2CHRNB2CHRNA3CHRNA4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205610-B1 | THIENOPYRIMIDIENE DERIVATIVES AS PI3K INHIBITORS | HOFFMANN LA ROCHE (CH) | 2013-11-20 | — | — | EP | disclosed |
| US-8293735-B2 | Thienopyrimidine derivatives as P13K inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021496-A1 | THIENOPYRIMIDINE DERIVATIVES AS P13K INHIBITORS | PIK3CA, PIK3CD, PIK3CB | NR1H2 3124/4885CHRNB2 4300/4885CHRNA3 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.